TY - JOUR
T1 - Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
AU - Larsen, Mathilde S.
AU - Bjerre, Karsten
AU - Lykkesfeldt, Anne E.
AU - Giobbie-Hurder, Anita
AU - Lænkholm, Anne Vibeke
AU - Henriksen, Katrine L.
AU - Ejlertsen, Bent
AU - Rasmussen, Birgitte B.
PY - 2012/10
Y1 - 2012/10
N2 - The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.
AB - The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.
KW - Breast cancer
KW - Endocrine resistance
KW - ER-positive
KW - HER-receptors
KW - Phosphorylated HER
UR - http://www.scopus.com/inward/record.url?scp=84865982782&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2012.07.005
DO - 10.1016/j.breast.2012.07.005
M3 - Article
C2 - 22854050
AN - SCOPUS:84865982782
SN - 0960-9776
VL - 21
SP - 662
EP - 668
JO - Breast
JF - Breast
IS - 5
ER -